An event regarding a size/fit issue involving a mets, distal femur, tibial component was reported.The event was confirmed by product inspection.Method & results: device evaluation and results: visual inspection: review of the tibial assembly (with the pre-assembled bumper pad) shows that each component is visually unremarkable with no evidence of misuse, shipping, handling, or storage damage.Dimensional and functional inspection comments: after decontamination, the tibial assembly was returned to stryker stanmore for assessment.Re-inspection of the assembly found the bumper pad to also be smaller in dimension, however the plastic component was reprocessed (heated & washed) when cleaned which can cause this difference.Re- inspection of the tibial component (lot number: b21461) confirmed that the distance between the dovetail features was oversized and out of specification.The dovetail feature retains the bumper pad in place when fully assembled.An oversized dovetail feature may lead to excessive clearance with the bumper pad and hence fail to retain the bumper pad in position before it is assembled with the femoral component.Clinician review: not performed as the alleged device was not implanted.Device history review: review of the product history records indicate devices were manufactured and accepted into final stock with no reported discrepancies.Complaint history review: based on the device identification the complaint databases were reviewed for similar events regarding a size/fit issue.Lot id: a21848.There have been no other events for the lot referenced.Conclusion: the investigation concluded that the size/fit issue was caused by the oversized dovetail feature of the tibial component, an oversized dovetail feature can cause excessive clearance with the corresponding bumper pad and could appear or feel loose or fail to retain the corresponding bumper pad.No further investigation is required at this time.If additional information becomes available to indicate further evaluation is warranted, this record will be reopened.Product surveillance will continue to monitor for trends.Corrective action/preventive action: on 09 february 2021 an nc was raised.
|